Immune Design advances first GLAAS™-based allergy program into clinical development
Immune Design announced the application of its GLAAS discovery platform in Sanofi’s Phase 1 clinical trial evaluating a novel therapeutic candidate for treatment of peanut allergy. The trial follows an exclusive license agreement with Immune Design to discover, develop and commercialize products. September 28, 2016